Cancer immunotherapy can confer durable benefit, but the percentage of patients who respond to this approach remains modest. The ability to concentrate immunostimulatory compounds at the site of disease can overcome local immune tolerance and reduce systemic toxicity. Surgical resection of tumors may improve the efficacy of immunotherapy by removing the concentrated immunosuppressive microenvironment; however, it also removes tumor-specific leukocytes as well as tumor antigens that may be important to establishing antitumor immunity. Moreover, surgery produces a transient immunosuppressive state associated with wound healing that has been correlated with increased metastasis. Using multiple models of spontaneous metastasis, we show that extended release of agonists of innate immunity-including agonists of Toll-like receptor 7/8 (TLR7/8) or stimulator of interferon genes (STING)-from a biodegradable hydrogel placed in the tumor resection site cured a much higher percentage of animals than systemic or local administration of the same therapy in solution. Depletion and neutralization experiments confirmed that the observed prevention of local tumor recurrence and eradication of existing metastases require both the innate and adaptive arms of the immune system. The localized therapy increased the numbers of activated natural killer (NK) cells, dendritic cells, and T cells and induced production of large amounts of type I interferons, thereby converting an immunosuppressive post-resection microenvironment into an immunostimulatory one. The results suggest that the perioperative setting may prove to be a useful context for immunotherapy, particularly when the release of the therapy is extended locally.
INTRODUCTION
Surgery is the most common intervention in oncology, but the resultant wound healing process can promote metastasis (1) , which accounts for 90% of cancer-related deaths (2) . Recurrence of primary tumors after surgery is associated with poor outcomes, increased local immunosuppression, and distant metastasis (3) . A set of genes that mediate breast cancer metastasis to lung has been identified and includes the immunosuppressive factor cyclooxygenase-2 (COX-2) (4). Consistent with this finding, perioperative administration of nonsteroidal anti-inflammatory drugs, which inhibit COX-2, reduces relapse (5) . This treatment is designed to counteract transient systemic inflammation that is caused by surgery. Such inflammation can initiate new metastases and awaken dormant existing micrometastases (6) , which can disseminate before manifestation of clinically detectable primary tumors (7, 8) . The immunosuppression associated with wound healing not only exerts direct effects on malignant tissue to promote cancer cell motility, invasion, and proliferation but also suppresses the activity of antitumor leukocytes, including cytotoxic T lymphocytes, natural killer (NK) cells, and dendritic cells (6) . Factors in the serum can promote a "wound-response" gene signature that predicts local recurrence (9) as well as metastasis and poor survival (10) . Because metastasis has such a grave impact on mortality, viable strategies to address metastasis are urgently needed.
Cancer immunotherapy is an attractive means of achieving longterm systemic immunosurveillance, but the response rate to immunotherapy requires improvement. In situ immunomodulation is a promising avenue of investigation. Notably, intratumoral immunotherapy is both safer and more effective than systemic administration (11) (12) (13) . Local delivery can elicit systemic antitumor immunity and lead to eradication of disseminated disease in mice, including in sites considered to be cancer cell sanctuaries (14) . The related "abscopal effect" after localized radiation therapy has been observed in a murine model of breast cancer (15) and in patients (16) . Concentrating the therapy at the site of disease allows one to break local immune tolerance, thereby enabling generation of systemic antitumor immunity in the absence of systemic exposure that can evoke severe side effects (17) .
Biomaterials and nanotechnology can be used to alter the colocalization, biodistribution, and release kinetics of immunomodulatory compounds, thereby improving the efficacy and safety of these molecules relative to systemic administration (18) . In one illustrative example underscoring the utility of immunoengineering, it was shown that the co-entrapment of an inflammatory cytokine, an immune danger signal, and a tumor antigen in a biodegradable scaffold controlled the activation and localization of host dendritic cell populations in situ, increasing vaccine efficacy (19, 20) . Scaffolds are particularly well suited to immunomodulation (21) . In another study, a scaffold was prepared to enhance the effectiveness of adoptive T cell therapy by delivering, expanding, and dispersing tumor-reactive T cells after incomplete tumor resection (22) . Here, we sought to determine whether it might be possible to produce curative outcomes among mice harboring established disease through extended release of immunomodulatory small molecules or biologics in the perioperative setting in the absence of a vaccine or adoptive cell transfer. We show that delivering cancer immunotherapy in a controlled spatiotemporal manner using a hydrogel scaffold confers superior efficacy to bolus injection of the therapy administered intraperitoneally, intravenously, or locally. The ability to prevent local recurrence and address metastases, both of which bode poorly for survival, is largely lacking.
We hypothesized that focusing immunotherapy at the site of interest in the intraoperative setting would prove beneficial. Specifically, we reasoned that it would be easier to eliminate a small number of residual cancer cells in the absence of a concentrated immunosuppressive microenvironment than to treat an intact primary tumor, which has many means of immune evasion-both innate and adaptive, cancer cell-intrinsic and cancer cell-extrinsic. Whereas the majority of current efforts in oncology focus on eliminating the primary tumor, modulating the immune compartment of the tumor resection microenvironment may represent a promising approach to treating cancer, including distal metastatic disease.
RESULTS

A hydrogel extends the release of immunomodulatory payloads
A hydrogel scaffold was prepared by cross-linking hyaluronic acid in a mold (Fig. 1A) . Hyaluronic acid is a U.S. Food and Drug Administrationapproved biopolymer that is naturally found in the body and has many desirable properties for biomedical applications, including its biocompatibility, ability to adopt many physical forms, and ability to control drug release spatiotemporally (23) . Most hyaluronic acid-based scaffolds are used for applications that involve encapsulation of cells, such as cell therapy and regenerative medicine (23) , but we required a hydrogel with greater stiffness than that commonly used. To ensure sufficient mechanical integrity for manipulation with tweezers, we prepared more than 20 formulations before arriving at an optimal ratio of crosslinker to polymer. To inspect the stability and confirm the degradability of the cross-linked hydrogel, a fluorescent dye was covalently conjugated to the scaffold ( fig. S1, A and B) . The scaffold was then placed into the tumor resection site of a female BALB/cJ mouse that had been inoculated orthotopically with syngeneic 4T1-Luc2 (luciferase) breast cancer cells. The fluorescently labeled scaffold was monitored by fluorescence in vivo imaging system (IVIS) imaging, and it was determined that noteworthy scaffold degradation began at 5 weeks, with complete resorption achieved by 12 weeks (Fig. 1B and fig. S1C ).
Mice whose tumors were resected exhibited cachexia, lethargy, and wet fur in the absence of perioperative therapy, whereas untreated mice appeared healthy and rarely died from the primary tumors; they were sacrificed because of their large tumor volumes rather than any apparent morbidity. Untreated mice harboring 4T1-Luc2 tumors had to be euthanized within 7 weeks of tumor inoculation (median survival, 40 days), and surgical removal of the tumors provided little survival benefit (median survival, 44 days), because mice succumbed to tumor recurrence and metastasis in this model ( fig. S1D ), as is often observed among breast cancer patients (24) . Because nearly all mice succumbed to disease after tumor resection alone, we repeated the in vivo degradation study in non-tumor-bearing mice, enabling us to increase the sample size. The shape of the scaffold degradation curve was very similar-including an apparent but modest decrease fig. S1 , E and F) of non-tumor-bearing mice to whom dye was administered in solution or conjugated to a hydrogel placed by the fourth mammary fat pad after incision. (D) Fluorescence IVIS imaging depicting the in vivo release profile of a model small-molecule payload (Cy7-CA), administered locally either in solution or after loading into a hydrogel. (E) Quantification of the in vivo release profile of Cy7-CA. The experiment was performed once with n = 5 biological replicates. Fold difference is indicated for each time point. Statistics were calculated using a two-sided unpaired t test. Data are means ± SD. *P ≤ 0.05, ***P ≤ 0.001, ****P ≤ 0.0001.
in signal intensity before the irreversible decline-to that of the lone surviving mouse whose tumor had been resected, although the scaffold's stability was prolonged by ~50% ( Fig. 1C and fig. S1E ). After 12 hours (early time point) or 15 weeks (later time point), the site of implantation was subjected to histopathological analysis. No abnormalities were detected by a certified pathologist (R. Bronson), confirming that the hydrogel is highly biocompatible. For comparison, a solution containing the fluorescent dye was administered locally, revealing that the free dye diffuses away very rapidly if it is not conjugated to the scaffold (Fig. 1C and fig. S1F ). These data confirm that cross-linked hyaluronic acid can serve as a stable, biodegradable depot.
We next examined the loading and release properties of the hydrogel. First, we assessed in vitro the ability of the hydrogel to release various payloads, including antibodies, cytokines, hydrophobic small molecules, and hydrophilic small molecules ( fig. S2 ). Under sink conditions in phosphate-buffered saline (PBS), the release kinetics ranged from hours to days, depending on the payload. We then confirmed that the hydrogel extends the release of the small molecules and biologics in vivo. Cyanine7 carboxylic acid (Cy7-CA) is a fluorophore that was used as a model small-molecule payload because its physical properties are very similar to those of resiquimod (R848), one of the compounds included in our studies. Cy7-CA was administered to non-tumor-bearing mice, either in solution or loaded in a scaffold placed by the fourth mammary fat pad. The mice were assessed by fluorescence IVIS imaging (Fig. 1D) , and the data were quantified (Fig. 1E) . Whereas a loss of ~60% of the signal was detected within 2 hours of administration of the fluorophore in solution, this amount of signal decay required 24 hours for the fluorophore loaded in the hydrogel. Over this time course, the signal for fluorophore released from the hydrogel was, on average, roughly threefold higher than fluorophore in solution.
To complement the study of small molecules, we examined the release kinetics of biologics in vivo. Confocal imaging of fluorescently labeled payloads demonstrated that antibodies, cytokines, and small molecules were distributed uniformly across the hydrogel ( fig. S3 , A to C). Fluorescently labeled versions of anti-PD-1 (programmed death 1), IL-15sa (interleukin-15 superagonist), or 2′3′-cGAMP (cyclic guanosine monophosphate-adenosine monophosphate) were administered to non-tumor-bearing mice, either in solution or loaded in a scaffold placed by the fourth mammary fat pad. The mice were assessed by fluorescence IVIS imaging ( fig. S3, D to F) , and the data were quantified ( fig. S3, G to I ). The release rates in vivo exhibited prolonged kinetics relative to those in vitro, as expected for an environment that is more physiologically relevant than sink conditions. These data confirm that the hydrogel scaffold can substantively extend the local release of immunomodulatory compounds relative to local delivery of the same compounds in solution.
To assess whether the function of the biologics was preserved after loading into and release from the cross-linked hydrogel, we compared the activity of unentrapped IL-15sa to IL-15sa that was recovered after entrapment and release. Specifically, we isolated central memory (CD44 Extended local release of agonists of innate immunity prevents tumor relapse and eliminates metastases Having confirmed that the release of these immunomodulatory compounds could be extended locally in vivo, we aimed to evaluate the utility of such extended delivery in the therapeutic setting. Female BALB/cJ mice were inoculated orthotopically with 4T1-Luc2 breast cancer cells in their fourth mammary fat pad. Nine days later, the mice were imaged by bioluminescent IVIS imaging, which confirmed that the size of the tumors was consistent across animals and enabled randomization into groups. On day 10 after tumor inoculation, tumors (~100 mm 3 ) were resected, and a hydrogel loaded with an immunomodulatory compound-anti-PD-1, anti-CTLA-4 (cytotoxic T lymphocyte antigen 4), IL-15sa, lenalidomide, celecoxib, 2′3′-cdi-AM(PS)2 (Rp,Rp) ("STING-RR"), or R848-was placed in the tumor resection site. Tumor burden was monitored weekly by IVIS imaging, and it was confirmed that local tumor recurrence was prevented most effectively when an agonist of innate immunity (STING-RR or R848) was administered via the hydrogel ( Fig. 2A) .
The STING (stimulator of interferon genes) agonist STING-RR stimulates tumor-resident dendritic cells to produce interferon- (IFN-), which is required for spontaneous tumor-initiated T cell priming (26) . This molecule has previously been investigated in the context of intratumoral injection into intact primary tumors (26) . R848 is a Toll-like receptor 7/8 (TLR7/8) agonist that induces expression of type I IFNs and costimulatory molecules by plasmacytoid dendritic cells as well as phenotypic maturation of conventional dendritic cells (27) . It is typically used as a vaccine adjuvant or as a topical treatment for viral or neoplastic skin lesions (28) .
Notably, the IVIS imaging revealed that lung metastases had already been established in the mice by the time of surgery, and extended local release of an agonist of innate immunity was again the lone condition that eradicated the existing metastatic lesions (Fig. 2A) . The IVIS imaging also provided a meaningful proxy for long-term survival such that only the hydrogel loaded with one of the agonists of innate immunity conferred durable survival benefit to a majority of mice (Fig. 2, B to D) .
Agonists of innate immunity are effective only when released locally from the hydrogel To confirm that extended release from the hydrogel was crucial to the observed efficacy, we compared various additional modes of administration of the agonists of innate immunity. For treatment with R848, in addition to no hydrogel and empty hydrogel controls, the following groups were evaluated: hydrogel (single dose), weekly intravenous injection, weekly intraperitoneal injection, and local delivery in solution (single dose) in conjunction with placement of an empty hydrogel (Fig. 3A) . The survival benefit was observed only when R848 was loaded in the hydrogel. To ensure that we were not missing efficacy afforded by delivery of R848 in solution owing to the fact that weekly administration was too long of a window between doses, we performed daily intraperitoneal injections for three consecutive days. Multiple systemic administrations of R848 failed to confer a robust survival benefit ( fig. S5A ), despite resulting in substantial weight loss ( fig. S5B ). Similarly, for treatment with STING-RR-which is considerably more potent than its natural analog 2′3′-cGAMP ( fig. S6 )-delivery via hydrogel was required to induce durable survival benefit among a majority of mice ( Fig. 3B and fig. S7 ).
Perioperative delivery of R848 or STING-RR from a hydrogel (Fig. 3 , A and B) was superior to intratumoral injection of either compound, which did not prolong survival ( Of note, intraoperative placement of the immunotherapy-loaded hydrogel was required for therapeutic benefit. Placement of hydrogels loaded with either R848 or STING-RR adjacent to nonresected tumors produced no survival benefit ( fig. S9 ), supporting the notion that the intervention is modifying the postsurgical resection microenvironment rather than treating an established tumor. Collectively, these results underscore the importance of having scaffold-mediated extended local release of the immunomodulatory payloads in the tumor resection site relative to administration of the compounds in solution, whether systemically, locally into the resection site as a bolus, or directly into the tumor.
To query the relative importance of immune stimulation versus leukocyte recruitment, we next loaded hydrogels with chemokines central to mediating antitumor immunity: CCL4 (C-C motif chemokine ligand 4), CCL5 (C-C motif chemokine ligand 5), and CXCL10 (C-X-C motif chemokine ligand 10). CCL4 is critical to recruitment of CD103 + dendritic cells (29) , whereas CCL5 and CXCL10 recruit T cells and are up-regulated in DNA damage response-deficient breast tumors, which exhibit constitutive activation of the STING pathway (30) . None of the chemokines conferred survival benefit (Fig. 3E ), nor did combination immune checkpoint blockade of anti-PD-1 and anti-CTLA-4 ( fig. S10 ). Similarly, neither paclitaxel nor doxorubicin loaded in hydrogels was efficacious in producing responses (Fig. 3F ), indicating that direct killing of residual cancer cells by cytotoxic agents locally does not protect against lethality caused by distal established metastases. Together, the data suggest that direct agonism of innate immune cells is important to achieving curative outcomes in a majority of treated mice.
Both innate and adaptive arms of the immune system are required for the observed efficacy
Knowing that R848 and STING-RR activate innate immune cells, we sought to discern whether there were particular downstream cells or pathways underlying the enhanced antitumor immune response upon extended local release of these compounds. To this end, we repeated the tumor inoculation and resection procedure described above, but, in addition to placing a hydrogel loaded with R848 or STING-RR in (F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times. For (A) and (B), statistics were calculated relative to the group treated with hydrogel containing R848 or STING-RR, respectively, using the log-rank (Mantel-Cox) test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. For (C) to (F), statistics were calculated relative to the no hydrogel control using the log-rank (Mantel-Cox) test, and no differences between groups were statistically significant. + T cells, and type I IFN signaling are each required to prevent tumor recurrence and metastasis. Mice in all groups whose innate or adaptive immune system was compromised failed to benefit from extended release of an agonist of innate immunity in the perioperative setting (Fig. 4) .
To dissect the cellular and molecular changes among immune cell subsets after localized release of R848, we assessed the composition, activation status, and function of leukocytes in the spleen. Spleens were recovered from mice 3 and 14 days after surgery for flow cytometric analysis. For the early time point-the so-called priming phase (31) (Fig. 5A) . We similarly observed increased numbers of CD8 + and CD103 + dendritic cells, which are crucial to cross-presentation and the production of robust antitumor immunity (29, 33) , as well as B220 + PDCA1
+ (plasmacytoid dendritic cell antigen-1) plasmacytoid dendritic cells, which secrete large amounts of type I IFNs (Fig. 5B) (33) . After exposure to R848, more dendritic cells expressed the costimulatory molecules CD40 and CD86 as well as MHC II (major histocompatibility complex class II), indicating that they had been activated. Similar findings were observed for NK cells and dendritic cells isolated from mice treated with hydrogels containing STING-RR ( fig. S12) .
The dendritic cells induced a strong adaptive antitumor response, as evidenced by the T cell compartment 14 days after surgery. Increased numbers of CD4 +
FoxP3
− T cells and CD8 + T cells that express markers of activation, including CD69 and glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), were detected (Fig. 5C ). Systemic immunity is required for effective cancer immunotherapy (31), and we confirmed an increase in the number of central memorylike CD8 + T cells that coexpress Ly6C and CD62L (Fig. 5D ), which become more prevalent with effective immunotherapy (31) .
To assess whether the inhibition of tumor recurrence and lung metastasis upon implantation of R848-loaded hydrogels is associated with systemic expansion of tumor antigen-specific CD8 + T cells, we restimulated splenocytes isolated from the treatment and control groups with SPSYVYHQF, an immunodominant peptide of murine leukemia virus envelope glycoprotein gp70 (amino acids 423 to 431), which is expressed by 4T1 cells (34) . The proportion of T cells expressing the proinflammatory cytokines IFN- and IL-2 as well as the cytolytic molecule granzyme B was increased among mice treated with hydrogels containing R848 (Fig. 5E ). These data confirm that the CD8 + T cells responded to the gp70 peptide restimulation in an antigen-specific manner.
Given the ability of the therapy to eliminate metastases that had already developed in the lungs, we also inspected the composition of leukocytes in lungs recovered 3 and 14 days after surgery. Increased numbers of B cells, T cells, NK cells, and dendritic cells were detected among mice treated with R848-loaded hydrogels ( fig. S13 ). Although these data do not suggest a particular mechanism that is responsible for eradication of metastases, they again support the notion that extended release of R848 promotes a broad systemic antitumor immune response.
To gain insights into the soluble factors that are associated with the activation of innate and adaptive immune cells, we measured the concentrations of cytokines in peripheral blood. At multiple time points after surgery, plasma was collected and subsequently analyzed by multiplexing laser bead technology. Consistent with the loss of efficacy after neutralization of IFNAR1-suggesting a role for type I IFNs-the concentrations of both IFN- and IFN- were markedly increased after treatment with a hydrogel containing R848 relative to no hydrogel (Fig. 5F ). The concentrations of several other soluble mediators of immunity were also noticeably increased, including CXCL10 (IP-10), CXCL9 (MIG), and IL-15 (fig. S14 and  table S1 ). Together, these results indicate an expansive induction of antitumor immunity. The induction of a memory response was confirmed by rechallenging the surviving mice, 100% of which rejected the 4T1-Luc2 cells that were freshly inoculated into the opposite mammary fat pad ( fig. S15 ).
The hydrogel and intervention are both safe
We confirmed the safety of both the hydrogel and extended local release of immunotherapy therefrom. Three or 14 days after tumor resection and placement of no hydrogel, an empty hydrogel plus local delivery of R848 or STING-RR, or a hydrogel loaded with R848 or STING-RR, whole blood was collected and subjected to a blood panel analysis. The composition of the blood was unaffected by the treatments (fig. S16 ). The lack of detectable systemic toxicity was confirmed by a lack of changes in the concentrations of liver enzymes (alanine aminotransferase were depleted, or innate immune signaling (IFNAR1) was inhibited to explore their relative contribution to the observed efficacy. Kaplan-Meier curves are shown for all groups described. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times. Statistics were calculated relative to the group treated with hydrogel containing the indicated agonist of innate immunity and treated with PBS (no depletion control) using the log-rank (Mantel-Cox) test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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and aspartate aminotransferase) and a surrogate of kidney function (blood urea nitrogen) in the blood across treatment groups ( fig. S17 ). Moreover, body weight was consistent across all groups tested, with the sole modest decrease being observed transiently after surgery, as expected subsequent to such stress ( fig. S18 ).
Efficacy is confirmed in additional models of spontaneous metastasis
Finally, we sought to demonstrate the broad utility of extended localized release of perioperative immunotherapy. In addition to confirming that the parental 4T1 cell line is as responsive as 4T1-Luc2 Splenocytes were cultured for 6 hours in the presence of a specific immunodominant peptide expressed by 4T1 cells (gp70 [423] [424] [425] [426] [427] [428] [429] [430] [431] ) and brefeldin A before flow cytometry was performed. (F) Increased concentrations of type I IFNs are observed in plasma collected at various time points after surgery. Data were generated by multiplexing laser bead technology. The experiment was performed once with n = 5 biological replicates. Statistics were calculated using a two-sided unpaired t test. Data are means ± SEM. *P ≤0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
cells to immunotherapy ( fig. S19 ), as previously reported (22), we inoculated C57BL/6J mice subcutaneously with Lewis lung carcinoma (LLC) cells or B16-BL6 melanoma cells, both of which also spontaneously metastasize to the lung. When tumor volumes reached ~500 or ~650 mm 3 , respectively, tumors were surgically resected. Again, longterm survival benefit was observed among mice implanted with hydrogels loaded with an agonist of innate immunity (Fig. 6 and fig. S20 ). Last, we generated hydrogels from alginate to establish that extended release of an agonist of innate immunity can be achieved using additional biomaterials and that such release prevents local recurrence and eliminates distal metastases. As with the hyaluronic acid-derived hydrogel, the amount of cross-linker (in this case, calcium chloride) had to be optimized to provide desirable mechanical integrity. The alginatebased hydrogel exhibited a similar in vitro release profile of R848 to that of the hyaluronic acid-based hydrogel ( fig. S21A ) and conferred similar survival benefit ( fig. S21B) .
DISCUSSION
This study demonstrates that extended release of immunotherapy from a hydrogel placed in a tumor resection site can prevent local tumor recurrence and induce systemic antitumor immunity that eradicates existing spontaneous metastases. The study of relapse and metastasis adds value in moving a drug candidate toward clinical development (35) . A given drug can exhibit differential efficacy depending on the degree of tumor progression at which the drug is administered (36) . Murine models that die owing to metastatic burden enable one to study the effects of a drug in the setting of metastatic cancer, which is the setting that is most frequently observed in the clinic. To mimic patient care accurately, scientists may consider removing the primary tumor, as surgeons do clinically (35) .
We primarily evaluated the orthotopic 4T1 tumor model because it robustly recapitulates many features of advanced human breast cancer. It is refractory to most therapeutic agents, including immunotherapy (37) . 4T1 breast cancer cells spontaneously metastasize from the primary mammary fat pad to distant sites, particularly the lungs (38) . Consistent with what is observed among patients, mice harboring 4T1 tumors generally succumb to metastatic disease, even if the primary tumor has been surgically removed (37, 38) . Surgery itself appears to reduce NK cell function, which is important for preventing postoperative metastasis in both mice and patients (39) . Our data indicate that orthotopic 4T1 tumors can be successfully treated with monotherapy, provided that the therapy is delivered in an extended manner in the perioperative setting.
Using the related 4T1.2 model, it was recently shown that the efficacy of immunotherapy is greatly enhanced if the therapy is administered in the neoadjuvant (preoperative) setting rather than in the adjuvant (postoperative) setting (40) . This was the case at least for immunotherapy directed at T cells, whether regulatory or effector. One of the proposed mechanisms underlying this observation is that the primary tumor is needed to expand tumor-specific T cells after administration of neoadjuvant immunotherapy. Cognate antigen is required to maintain the survival of effector T cells, whose numbers decrease dramatically after surgery (41) . In contrast, central memory T cells do not depend on antigen for their maintenance (40) , which may partially explain the efficacy that we observe after perioperative immunotherapy. Notably, resection of primary tumors removes not only sources of neoantigens but also effector cells and potentially supportive T helper 1 (T H 1) cytokines, which are important for antitumor responses and whose removal may account for the limited efficacy of adjuvant immunotherapy.
Although neoadjuvant immunotherapy is an exciting avenue of investigation, perioperative immunotherapy may be superior. Surgery can reduce primary resistance to immunotherapy by removing cancer cell-intrinsic mechanisms of resistance (42) . Moreover, it can remove cancer cell-extrinsic factors that promote primary and adaptive resistance, such as immunosuppressive regulatory cells that are often found in high numbers in the tumor microenvironment. Myeloidderived suppressor cells promote metastasis and are correlated with reduced survival as well as decreased responsiveness to immunotherapy (42) . In addition, the improved survival conferred by neoadjuvant immunotherapy in the 4T1.2 model required combination therapy and may be limited to therapies that activate T cell-mediated antitumor immunity, and neoadjuvant immunotherapy may necessitate inadvisable delays in surgery owing to induction of immune-related adverse events (40) . Although it is generally thought that earlier treatment with immunotherapy would be beneficial, side effects after systemic administration have limited such studies to date (43) . Localized therapy is expected to reduce such systemic toxicity. Intraoperative placement of a scaffold also obviates the need to optimize the scheduling of immunotherapy administration, which is required in the neoadjuvant setting and may be particularly challenging for combination therapies. The perioperative setting represents a consequential timeframe for intervention, because surgical stress causes acute immunosuppression that must be overcome to prevent recurrence and dissemination (6) . Expression of genes related to wound healing is associated with a lack of response to anti-PD-1 treatment (44) . Converting the perioperative period from a pronounced augmenter of metastatic progression to a window of opportunity for halting and/or eradicating residual disease is expected to improve long-term survival rates (45) . The utility of intraoperative placement of a scaffold was previously demonstrated in the context of adoptive cell therapy for treatment of inoperable or incompletely removed tumors, such as 4T1 (22) . A porous biopolymer implant was used to enhance the proliferation, migration, and function of tumor-reactive T cells, thereby reducing tumor relapse relative to administration of lymphocytes in solution.
More recently, such implantable biopolymer devices were used to deliver chimeric antigen receptor (CAR) T cells directly to the surfaces of solid tumors (46) . Although the efficacy of adoptive cell therapy was vastly improved by loading a STING agonist into immunostimulatory microparticles that were incorporated into the scaffolds, the benefit required the STING agonist to be co-delivered in the scaffolds containing tumor-specific CAR T cells. The STING agonist did not confer a profound impact when administered in solution, in the scaffold in the absence of CAR T cells, or in the scaffold in the presence of control CAR T cells. Our data demonstrate that it is possible to confer durable survival benefit among mice harboring established spontaneous metastases using an off-the-shelf scaffold that is not loaded with exogenous T cells, antigen-specific or otherwise, even when gross residual tumor antigen is not intentionally left behind. These findings reveal that relatively high numbers of cancer cells are not required at the time of immunotherapy to enable cross-priming of tumor antigen.
Treating in the perioperative setting, wherein primary tumor antigen and antigen-specific T cells are removed, is distinct from treating intact solid tumors or incompletely resected tumors. Most current tactics in immunotherapy rely on the presence of tumor-infiltrating lymphocytes (TILs), and the dearth of such TILs in many solid tumors represents a major challenge (47) . Although extended local release of celecoxib and anti-PD-1 from an alginate hydrogel injected subcutaneously in the region adjacent to 4T1 tumors conferred some survival benefit relative to local administration of free drug, no durable responses were observed, despite the presence of tumor antigen (48) . Administration of hydrogels in the perioperative setting may be superior to local injection of hydrogels.
The findings reported herein underscore the importance of having a depot to achieve extended local release of an agonist of innate immunity after surgical resection of a tumor to prevent local tumor recurrence and clear established distal metastases. The resultant impact on the immune system is broad, as evidenced by cellular and molecular analyses of systemic leukocyte populations. Antitumor efficacy required involvement of both innate and adaptive immunity, and type I IFN signaling was indispensable. The data suggest that intraoperative placement of scaffolds containing immunotherapy may be worthy of clinical investigation. Because the hydrogels described in these studies can release both small molecules and biologics, many options-including combinations-can be explored in future work.
This intervention modulates the tumor resection microenvironment and stimulates innate immunity during the period of acute immunosuppression that is associated with wound healing, which is known to promote metastasis. The platform is therefore limited to surgically resectable tumors and is not designed to address intact primary tumor masses in the absence of surgery. The finding that modifying the tumor resection microenvironment is different than addressing intact primary tumors (whole or residual) has bearings on both biological and clinical perspectives. Specifically, agonizing the innate immune system in the perioperative setting-before reestablishment of a concentrated immunosuppressive microenvironment after relapse-is sufficient to confer durable survival benefit and induce antitumor memory.
The results of these studies have particular translational relevance to agonists of STING, a highly promising therapeutic target. Whereas previous studies involved multiple intratumoral injections of the STING agonist (26) , our studies involved a single administration to enable us to compare the effects of a single dose of agonist in the presence or absence of concentrated tumor antigen and tumor-infiltrating leukocytes. The data reveal that a single dose of STING agonist is efficacious only in the context of stimulating the post-resection microenvironment and is insufficient to reverse established disease in the 4T1 model. Although multiple intratumoral injections are feasible in the clinical setting, we were not seeking to compare this regimen with perioperative therapy, because the individuals who would receive these therapies come from different patient populations. Rather, our objective was to demonstrate that a single administration of STING agonist (released locally from a hydrogel placed in the tumor resection site) would allow oncologists to intervene even when lesions are not superficially accessible. The requirement for superficial accessibility is a major limitation of intratumoral administration, because the vast majority of cancer patients have tumors that are not readily accessible. In contrast, the hydrogel can be administered during any surgical oncology procedure, which is the main treatment option for most solid tumors.
A second major difference between our data and those reported previously in the literature is the location and context of the tumor. Specifically, previous reports involved intratumoral injection into subcutaneous flank tumors (26) , whereas the 4T1 tumors in our study were implanted orthotopically into the mammary fat pad. Orthotopic tumors are much more challenging to cure than subcutaneous tumors, because tissues in different anatomical sites can shape and alter the tumor microenvironment to influence responses to therapy (49) .
Agonism of the innate immune compartment of the tumor resection microenvironment is seemingly critical to the observed efficacy. The survival data suggest that activating the adaptive immune system [via immune checkpoint blockade (50) or immunomodulatory imide drug (iMiD) (51)] or inhibiting immunosuppressive myeloid cells [celecoxib (52) ] was apparently insufficient to confer efficacy in the perioperative setting as monotherapy. IL-15sa, which is a highly potent complex of IL-15 and IL-15R sushi domain that expands NK cells and CD8 + T cells (32) , conferred a modest benefit, indicating that driving proliferation of effector cells may be less important than stimulating upstream innate cells that produce type I IFNs. Although doxorubicin has been reported to induce immunogenic cell death that results in cancer cell-autonomous production of type I IFNs (53), surgery removes the vast majority of the cancer cells from the tumor site, which may explain the lack of benefit afforded by doxorubicin in this setting. The observation that this cytotoxic drug is deleterious relative to no treatment may be explained by the fact that doxorubicin induces severe myelosuppression (54) . Whereas agonists of innate immunity can boost antitumor responses by stimulating dendritic cells and/or macrophages, doxorubicin has an opposing effect by killing these cells.
Although it is possible that mediators of adaptive immunity may also confer benefit in the context of extended localized release of perioperative immunotherapy, such benefit was not observed at the doses evaluated in the experiments presented herein. To account for the fact that intraoperative administration was performed only once, whereas systemic administration can be performed repeatedly, the experiments were performed with doses that are threefold higher than those routinely administered systemically or even locally for anti-PD-1 and anti-CTLA-4 (22, 37, 40, 48) . Even the combination of anti-PD-1 and anti-CTLA-4 administered at 300 g (rather than 100 g) each failed to confer benefit. Still, it remains possible that other combinations or further increased doses may prove useful. Local retention of mediators of immune checkpoint blockade after peritumoral injection increases efficacy and decreases systemic toxicity relative to administration of clones of the same antibodies that were not modified to be retained locally but rather rapidly diffuse systemically (55) . These data suggest that immune checkpoint blockade in the local environment suffices in the context of intact tumors and may be superior to systemic blockade of PD-1 and CTLA-4. Unfortunately, postoperative combination immunotherapy targeting the adaptive immune system is relatively ineffective (40) , again demonstrating that there is an unmet need to address the perioperative setting if preoperative therapy, wherein tumor antigen and antigen-specific T cells are present, is not an option.
The results presented herein suggest that imidazoquinolines such as R848 and cyclic dinucleotides such as STING-RR loaded in biodegradable hydrogels can be applied to the clinic and may have a meaningful impact on patient survival. Agonists of TLR7/8 or STING can serve as adjuvants at the tumor resection site, reprogramming an immunosuppressive environment into an immunostimulatory one and thereby stimulating systemic antitumor immunity. Translation will require selection of a preferred active pharmaceutical ingredient and a preferred polymer, such as hyaluronic acid or alginate. This platform has the potential to deliver immunotherapy in a spatiotemporally defined manner that focuses the therapy at the site of interest during a critical time window.
MATERIALS AND METHODS
Study design
The objective of this study was to determine whether extended local release of particular classes of cancer immunotherapy from a hydrogel placed in the tumor resection site could improve survival relative to local or systemic administration of the same compounds in solution. Mice bearing orthotopic or subcutaneous tumors that spontaneously metastasized were used for these controlled laboratory experiments. It was confirmed in vitro and in vivo that the hydrogel could prolong the release profile of the payloads, whether they were small molecules or biologics. A variety of anticancer modalities were compared, including mediators of immune checkpoint blockade, agonists of innate immunity, chemokines, and chemotherapy. Bioluminescence imaging (BLI) was used to inspect for local tumor recurrence and distal metastatic progression. Tumor volume was measured using electronic calipers when tumors were not surgically removed. Survival was selected prospectively as a primary endpoint. For mechanistic studies, flow cytometry and multiplexing laser bead technology were used to assess cell populations and soluble cytokines, respectively. Safety and tolerability were evaluated by measuring the composition of blood, liver enzyme concentrations, a surrogate of kidney function, and weight. Induction of an antitumor memory immune response was confirmed by rechallenging mice with a fresh inoculate of cancer cells.
The sample sizes were selected on the basis of the results of pilot experiments so that relevant statistical tests could reveal significant differences between experimental groups. No samples or animals that received treatment were excluded from the analysis. Mice were randomized twice before administration of therapy. For the 4T1 model, mice were randomly assigned to new groups of five mice per cage 7 or 8 days after tumor inoculation. After BLI measurements on day 9, mice whose tumors were extremely small or large, as determined by photon number, were excluded from enrollment in the studies. Specifically, mice were excluded if the photon number emitted by their tumors was threefold (or more) greater or less than the average. Mice were randomly assigned to treatment groups, and surgery was performed the following day (10 days after tumor inoculation). For the LLC and B16-BL6 models, tumor volume was measured using electronic calipers, and mice were randomized as tumor volumes approached 500 and 650 mm 3 , respectively. The investigator was blinded to the group allocation before surgery. The surgeries were performed independently at least three times, and the surgeon was blinded when the experiment allowed.
Cell lines
The metastatic murine 4T1 breast cancer (American Type Culture Collection, CRL2539) and B16-BL6 melanoma [provided by G. Merlino, National Institutes of Health (NIH)] cell lines were cultured in complete RPMI 1640 medium with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 1% l-glutamine. The 4T1-Luc2 breast cancer cells (Perkin Elmer) used for in vivo BLI were cultured the same way. The murine LLC lung cancer cell line [provided by H. Cantor, Dana-Farber Cancer Institute (DFCI)] was cultured in complete Dulbecco's modified Eagle's medium with 10% FBS, 1% penicillin/ streptomycin, and 1% sodium pyruvate. Cells were tested for mycoplasma contamination and found to be negative.
Mice
Animal experiments were carried out in accordance with protocols approved by the DFCI Institutional Animal Care and Use Committee. For the metastatic breast cancer model, female BALB/cJ mice (6 to 8 weeks old) were purchased from the Jackson Laboratory (stock #000651). For the lung cancer model, female C57BL/6J mice (6 to 8 weeks old) were purchased from the Jackson Laboratory (stock #000664). Mice were housed in the animal facility of DFCI.
Preparation of hydrogel
HyStem hydrogel kits (ESI Bio, GS1004) were used to prepare the hydrogels. A Teflon mold (9 mm diameter) was first filled with 120 l of Glycosil (thiol-modified hyaluronic acid), and then 200 g of R848 (Sigma, SML0196) or 100 g of c-di-AM(PS)2 (Rp,Rp) (Invivogen, tlrl-nacda2r) was added. For comparative studies, 300 g of rat antimouse PD-1 (anti-PD-1) (BioXCell, clone 29F.1A12), 300 g of hamster anti-mouse CTLA-4 (anti-CTLA-4) (BioXCell, clone 9H10), 3 g of mouse IL-15/IL-15R complex recombinant protein carrier-free (IL15sa) (eBioscience, 34-8152-82), 100 g of 2′3′-cGAMP (Invivogen, tlrl-nacga23), 200 g of lenalidomide (Sigma, CDS022536), 1500 g of celecoxib (Selleckchem, S1261), 10 g of CCL4 (R&D Systems, 451-MB/CF), 10 g of CCL5 (R&D Systems, 478-MR/CF), 10 g of CXCL10 (R&D Systems, 466-CR/CF), 100 g of paclitaxel (Selleckchem, S1150), or 100 g of doxorubicin (Selleckchem, S1208) was added. Next, 30 l of Extralink [thiol-reactive PEGDA (polyethylene glycol diacrylate) cross-linker] was added into the mold, and the hydrogel was allowed to cross-link for at least 1 hour (pH 6.8 to 6.9). For in vitro release studies and confocal imaging, anti-PD-1 and IL-15sa were fluorescently tagged with Alexa Fluor 405 NHS Ester (Thermo Fisher Scientific, A30000) and the VivoTag 680XL Protein Labeling Kit (Perkin Elmer, NEV11118), respectively, according to the manufacturer's guidelines, and fluorescein-tagged 2′3′-cGAMP (BIOLOG Life Science Institute, C195) was used as a model compound for 2′3′-c-di-PS(2) (Rp,Rp). For in vivo imaging, both anti-PD-1 and IL-15sa were fluorescently labeled with VivoTag 800 (Perkin Elmer, NEV11107), and Cy7-CA (Abcam, ab146499) and sulfo-Cy7-labeled 2′3′-cGAMP (BIOLOG Life Science Institute, custom order) were used. For evaluation of in vivo degradation of the hydrogel, 1.2 l of Alexa Fluor 750 C5-maleimide (Molecular Probes, A30459) was conjugated directly to the hydrogel. Alginate hydrogels were prepared by filling a Teflon mold with 200 l of sodium alginate solution (Amsbio, AMS.CSR-ABC-AL) and then adding 200 g of R848 followed by 15 l of 1 M calcium chloride (bioWORLD, 40320005). The hydrogel was allowed to set for at least 30 min. Protein conjugation and hydrogel preparation were done under sterile conditions.
Confocal microscopy
To assess the distribution of the payloads within the hydrogel, a hydrogel loaded with fluorescently tagged anti-PD-1, IL-15sa, or 2′3′-cGAMP was imaged under a confocal laser scanning microscope (Leica TCS SP8 STED CW; Leica Microsystems). The obtained images were processed using Leica LAS AF software (Leica Microsystems).
In vitro release study
To determine the release kinetics of each payload from the hydrogel, a hydrogel loaded with fluorescently tagged anti-PD-1, fluorescently tagged IL-15sa, lenalidomide, celecoxib, fluorescently tagged 2′3′-cGAMP, or R848 was immersed in 3 ml of PBS (pH 7.4). At each time point, 1 ml of medium was taken out and the same amount of fresh buffer was added back. The amount of payload that had been released was then measured using a fluorescence plate reader or via high-performance liquid chromatography (HPLC). For anti-PD-1, the fluorescence signal was measured at an excitation of 400 nm and an emission of 430 nm. For IL-15sa, the fluorescence signal was measured at an excitation of 660 nm and an emission of 690 nm. For 2′3′-cGAMP, the fluorescence signal was measured at an excitation of 490 nm and an emission of 520 nm. For the remaining small molecules, the amount of drug was determined via HPLC (Agilent Technologies, 1260 series) using an Inspire column (Dikma Technologies, Inspire 5 m C18, 250 × 4.6 mm). The mobile phase was prepared by mixing a 20 mM solution of PBS at pH 2.5 with acetonitrile (7:3, v/v). The flow rate and injection volume were 1 ml/min and 20 l, respectively. The ultraviolet (UV) absorbance was measured at 230 nm.
Functional analysis of released IL-15sa
To assess whether the activity of IL-15sa was preserved after loading into and release from the cross-linked hydrogel, we evaluated the pro- sodium pyruvate, and 55 M 2-mercaptoethanol. All supplements were obtained from Life Technologies. Unentrapped IL-15sa or IL-15sa released from a hydrogel (using the conditions described in the preceding section) was added at 100 ng/ml. To block CD122, anti-CD122 (BioLegend, clone TM-) was also added at 10 g/ml. The cells were incubated for 4 days, and proliferation was confirmed using a BD LSRFortessa X-20 (BD Biosciences). Dead cells were excluded using 7-aminoactinomycin-D (7-AAD) staining (BioLegend, 420404). Cells were cultured in at least triplicate wells, and the experiments were conducted independently in triplicate.
In vivo evaluation of hydrogel degradation
In vivo degradation of fluorophore-labeled hydrogels was monitored using the IVIS Spectrum In Vivo Imaging System (Perkin Elmer) after the hydrogels were surgically implanted into mice. Fluorescence imaging was obtained weekly and analyzed with Living Imaging software (Perkin Elmer). Both tumor-resected mice and non-tumor-bearing mice were tested for in vivo hydrogel degradation, although only one tumor-resected mouse survived for more than a few weeks in the absence of therapy, because tumors recurred in nearly all animals receiving surgery alone.
In vivo release study
To evaluate the in vivo release profiles of Cy7-CA (a model compound for R848), anti-PD-1, IL-15sa, and 2′3′-cGAMP, hydrogels containing the fluorophore or one of the fluorescently labeled payloads were surgically implanted into non-tumor-bearing mice. For controls, solutions containing the fluorescent molecules were administered into the incision sites. Fluorescence was monitored using the IVIS Spectrum In Vivo Imaging System (Perkin Elmer).
In vivo tumor models and treatment
For the metastatic breast cancer model, 10 5 4T1-Luc2 or 4T1 cells [in 30 l of Dulbecco's PBS (DPBS)] were inoculated orthotopically into the fourth mammary pad of mice to generate a local tumor mass. Cells were injected without any incision to expose the fat pad. Mice were randomly assigned to treatment groups, and surgery was performed 10 days after tumor inoculation. For the metastatic lung cancer and melanoma models, 5 × 10 5 LLC cells or 10 6 B16-BL6 cells (in 100 l of DPBS), respectively, were inoculated subcutaneously into mice to generate a local tumor mass. Mice were randomly assigned to treatment groups, and surgery was performed when tumor volumes reached ~500 or ~650 mm 3 , respectively. While mice were kept under anesthesia at 2% isoflurane, the tumor was resected, and the hydrogel was placed in the site of the resultant cavity at the time of surgery. The wound was closed with medical clips. In control experiments, therapy was administered in solution at the site of surgery, intraperitoneally or intravenously. For tumor rechallenge experiments, 10 4 4T1-Luc2 cells were inoculated in the contralateral mammary fat pad. The surgeries were performed independently at least three times, and the surgeon was blinded when the experiment allowed.
In vivo bioluminescence and imaging
After surgery, mice were inspected by BLI weekly for local tumor recurrence and distal metastasis. To this end, 10 min after intraperitoneal injection of d-luciferin (150 mg/kg), a substrate of Luc2, the mice were anesthetized with 2% isoflurane and imaged using the IVIS Spectrum In Vivo Imaging System (Perkin Elmer).
Depletion of NK cells, CD8 + T cells, or CD4 + T cells and neutralization of IFNAR1
To evaluate which immune cells are required to confer the observed antitumor effect, specific cell subsets (NK cells, CD8 + T cells, or CD4 + T cells) were depleted by administering a depleting antibody intraperitoneally every 3 days, beginning 1 day before therapy. The antibodies used for depletion were anti-asialo GM1 (polyclonal, Wako Chemical, 30 l), anti-mouse CD8a (clone 2.43), and anti-mouse CD4 (clone GK1), respectively. To test the role of type I IFN signaling, a neutralizing antibody against IFNAR1 (clone MAR1-5A3) was administered to the mice. All antibodies were purchased from BioXCell, and 200 g of antibody was used, unless otherwise specified. Depletion of NK cells, CD8 + T cells, or CD4 + T cells was confirmed by flow cytometry of leukocytes isolated from the blood of mice to which antibodies or PBS had been administered.
In vivo cytokine analysis
Blood was collected from mice 1.5 hours, 6 hours, 3 days, and 14 days after resection of tumor and treatment with an R848-loaded hydrogel or no hydrogel. Plasma was sent to Eve Technologies to measure the concentrations of circulating cytokines that were produced in response to the therapy. The MD-31 panel (days 3 and 14) was complemented by assessment of IFN- and IFN- (hours 1.5 and 6).
Flow cytometry
Flow cytometry was performed on a BD LSRFortessa X-20 (BD Biosciences), and all antibodies were purchased from BioLegend, eBioscience, or BD Biosciences (listed in table S2). For restimulation studies, SPSYVYHQF (purity >95%), an immunodominant peptide of murine leukemia virus envelope glycoprotein gp70 (amino acids 423 to 431), was used (New England Peptide, BP10-470). GolgiPlug (BD Biosciences, 555029) was used for inspection of intracellular cytokines and cytolytic molecules.
Statistical analysis
Statistical methods were not used to predetermine sample size. The sample sizes were selected on the basis of the results of pilot experiments so that relevant statistical tests could reveal significant differences between experimental groups. Statistical analysis was performed using GraphPad Prism software version 7.01. Data are presented as means ± SD or means ± SEM, as indicated in the figure legends. To determine statistical significance when comparing two groups, the two-sided unpaired t test was used. For survival analysis, the log-rank (Mantel-Cox) test was used.
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